Rayca Science Developability
Many development liabilities are visible in the chemistry long before anyone measures them. Rayca carries solubility, permeability, metabolism, solid form and, for biologics, manufacturability through every design decision, and learns them from the evidence your institution already holds.
The problem
Developability is usually assessed after the chemistry has been committed. By then, every correction is expensive.
Where research and development loses time and evidence today, read against how Rayca changes each point.
Assessed at the gate
Developability is commonly evaluated at candidate nomination, once the series and its scaffold are fixed. Liabilities found at that point leave a choice between costly redesign and carrying the risk into development.
A profile from the first design
Every design carries a predicted developability profile, with its uncertainty, from the first cycle of lead optimisation.
Properties optimised in sequence
Potency is pursued first and properties are repaired afterwards. The trade-offs between them are negotiated informally, one meeting at a time, and are rarely recorded.
Trade-offs made explicit
Each proposed change shows what it gains and what it costs across every property, so the project team chooses its balance deliberately.
Institutional experience left unused
An organisation’s history of solid-form surprises, metabolic liabilities and biologic aggregation resides in development reports that discovery teams seldom consult.
Models trained on your development history
Developability models learn from your own late-stage evidence, so what development has already learned informs discovery.
Solid form and stability found by surprise
A more stable crystal form, poor solubility of the form that crystallises, or chemical degradation under storage can appear late, when material and timelines are least forgiving.
Solid form and stability assessed early
Crystal packing, form risk and degradation pathways are assessed computationally while the chemistry can still change.
Designed in, not screened out 01
Candidates reach nomination with fewer liabilities left to discover.
When developability becomes known
Cost of change across a program01The conventional path
02Profile from the first design
03Improve cycle by cycle
Properties are measured in depth only as nomination approaches.
A profile for every design 02
Property risk is weighed with its evidence, not assumed.
Developability profile
Estimate, interval and acceptable range01Predict together
02State confidence
03Refine on your data
04Compare designs
All properties are estimated for each design at once.
Solid form and solubility 03
Form risk is assessed while it can still be designed away.
Crystal energy landscape
Predicted packings by density and lattice energy01Generate packings
02Rank by energy
03Find the risk
04Inform the screen
Candidate crystal structures are built for the molecule.
Metabolism and clearance 04
Clearance is shaped atom by atom, with its consequences visible.
Sites of metabolism
Predicted on the structurePredicted sites
- O-dealkylation
- N-dealkylation
- Aromatic oxidation
After the edit
- Metabolic stabilityImproved
- PotencyHeld
- SolubilityHeld
- PermeabilityHeld
01Predict the sites
02Propose protection
03Check the balance
Atoms most likely to be metabolised are located.
Biologic developability 05
Biologics are designed to be made, formulated and given.
Sequence and surface
Track view of one binding domain01Map the surface
02Read the sequence
03Propose variants
Hydrophobic and charged patches on the modelled structure.
Trade-offs in the open 06
Every nomination carries the reasoning behind its compromises.
Choosing the balance
Potency against developabilityDecision record
- The balance chosen for the intended product
- Properties accepted, and why
- Alternatives the team considered
Travels with the candidate
01Lay out the candidates
02Find the frontier
03Choose and record
Against the properties the intended product needs.